Mimedx (MDXG) Receivables - Other (2017 - 2021)

Mimedx (MDXG) posted Receivables - Other of $400000.0 for Q2 2021, down 42.86% sequentially from $700000.0 in Q1 2021.

Mimedx (MDXG) Receivables - Other (2017 - 2021) Analysis & Trends

Mimedx has reported Receivables - Other for 5 years, with the latest figure at $400000.0 in Q2 2021.

Quarterly Receivables - Other changed N/A year-over-year to $400000.0 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $400000.0 (changed N/A YoY) and the FY2020 annual result came in at $200000.0, down 84.62% from the prior year.
Receivables - Other fell to $400000.0 in Q2 2021 per MDXG's latest filing, from $700000.0 in the prior quarter.
Over five years, Receivables - Other peaked at $5.9 million in Q4 2017 and troughed at $200000.0 in Q4 2020.
A 5-year average of $2.0 million and a median of $1.0 million in 2019 frame the typical range for Receivables - Other.
The sharpest annual moves came in 2020 and 2021: Receivables - Other plunged 84.62% in 2020, then rose 16.67% in 2021.
Over 5 years, Receivables - Other stood at $5.9 million in 2017, then declined by 27.12% to $4.3 million in 2018, then sank by 69.77% to $1.3 million in 2019, then slumped by 84.62% to $200000.0 in 2020, then surged by 100.0% to $400000.0 in 2021.
According to Business Quant data, Receivables - Other over the past three periods registered $400000.0, $700000.0, and $200000.0 for Q2 2021, Q1 2021, and Q4 2020 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Mimedx	622.24 Mn	486.40 Mn	44.38 Mn

Download Data